Anika Therapeutics, Inc.
No enriched coverage for $ANIK in the last 7 days.
No SEC Form 4 filings for $ANIK in the last 30 days.
Anika Therapeutics' CEO, Stephen Griffin, acquired 12,200 shares of the company's common stock for $149,880 after a recent stock drop. This purchase increased his direct holdings to 36,163 shares and occurred despite the company reporting strong Q1 2026 financial results that exceeded expectations. The context suggests a CEO's confidence in the company following a market dip.
Anika Therapeutics' President and CEO, Stephen D. Griffin, purchased 12,200 shares of the company's common stock on April 30, 2026, at a weighted average price of $12.2853 per share, totaling approximately $150,000. Following this open-market transaction, Griffin directly holds 36,163 shares of ANIK. This insider buying signals positive sentiment from the company's leadership regarding its prospects.
Anika Therapeutics (ANIK) reported Q4 2025 revenue of US$30.6 million and basic EPS of US$0.13, showing a shift towards profitability from previous losses. Despite this positive quarterly performance, the company's trailing twelve-month revenue was US$112.8 million with a net loss of US$10.0 million and basic EPS of -US$0.70. Analysts predict Anika will remain unprofitable for the next three years, though its current P/S ratio and valuation suggest potential upside if it achieves promised profit margins.
